Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 8, 2019
Daily News
November 8, 2019
- China Emerges as a Key Destination for New Clinical Trials in 2018: Informa Report
November 8, 2019
- Japan Market Logs Hefty 8.9% Growth in July-September: IQVIA
November 8, 2019
- Opposition Party Set to Compile HPV Vaccine Proposal by Year-End
November 8, 2019
- AstraZeneca’s COPD Triplet Promotion Stands Out in August: Impact Track
November 8, 2019
- Keytruda Stays on Top in October Japan Drug Ranking: Encise
November 8, 2019
- National Neurology Center Starts Investigator-Led Trial for DMD Drug Targeting Exon 44
November 8, 2019
- Takeda’s Dengue Vaccine Candidate Showed Confirmed Protection Efficacy in PIII
November 8, 2019
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…